# Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

> **NCT02781883** · PHASE2 · RECRUITING · sponsor: **Bio-Path Holdings, Inc.** · enrollment: 108 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** BP1001 in combination with Ventoclax plus decitabine
- **DRUG:** BP1001 plus decitabine

## Key facts

- **NCT ID:** NCT02781883
- **Lead sponsor:** Bio-Path Holdings, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-05
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02781883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02781883, "Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02781883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*